|
Dear Cornerstone Investor:
We thought you may be interested to know that Cornerstone was included in a recent SciBX article: " Targeting T cell metabolism." SciBX is a weekly sister publication to Nature and Biocentury and provides analysis of the most promising science and technology from a scientific and business perspective. Cornerstone's Vice President of Research Paul Bingham, Ph.D, , was quoted in the story and information on Cornerstone's lead drug CPI-613 was included.
All the best,
The Investor Relations Team at Cornerstone
|
By Chris Cain
Published: March 3, 2011
Researchers at the University of Michigan have shown that modulating ATP synthase activity can selectively kill alloreactive T cells and arrest graft versus-host disease. Lycera Corp. has licensed the findings, which may provide a new indication for the small molecule partial inhibitors of ATP synthase that the company plans to advance into the clinic this year.
|
